Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing

BACKGROUND: Telithromycin (Ketek) was approved in April 2004 for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), bacterial sinusitis, and community-acquired pneumonia. The approval of telithromycin was controversial due to trial irregularities, noninferiority study desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleason, Patrick P., Walters, Carol, Heaton, Alan H., Schafer, Jeremy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2007
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437775/
https://www.ncbi.nlm.nih.gov/pubmed/17605513
http://dx.doi.org/10.18553/jmcp.2007.13.5.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437775/
https://www.ncbi.nlm.nih.gov/pubmed/17605513
http://dx.doi.org/10.18553/jmcp.2007.13.5.420

Ejemplares similares